Drug Profile
LY 306740
Latest Information Update: 01 Aug 2002
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Nonindustrial source
- Class Acetamides; Anti-inflammatories; Antiasthmatics
- Mechanism of Action Neurokinin 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 18 Jan 2000 New profile
- 18 Jan 2000 Preclinical development for Pain in Germany (Unknown route)
- 18 Jan 2000 Preclinical development for Pain in Portugal (Unknown route)